The delay of the DENALI Part 2 topline readout from year-end 2026 to 1H 2027 pushes back the key catalyst and any potential FDA submission. The August follow-on offering diluted existing holders by ~27% (26.45M shares on 98.3M outstanding). Monitor FDA discussions in 2027 and the DENALI readout for the next major catalyst.
Drug in focus
ZNTL drug pipeline →azenosertib
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2 (registration-intent) with Phase 3 confirmatory trial initiated
- Time to market
- If the DENALI Part 2 readout in 1H 2027 is positive, Zentalis plans to discuss an accelerated approval pathway with the FDA in 2027. Under an accelerated approval scenario, a potential FDA decision could come in 2028 at the earliest, though the timeline is uncertain and depends on regulatory feedback.
- Next catalyst
- None dated
What to watchThe next major catalyst is the DENALI Part 2 topline readout expected in 1H 2027 (roughly 2-7 months away). A positive readout could support an accelerated approval filing with the FDA; a negative or mixed readout would likely devastate the stock given Zentalis is a single-asset company. The August 2026 delay from year-end 2026 to 1H 2027 was a negative signal, and the stock now trades at $1.74, well below the $3.50 August offering price. Monitor FDA discussions in 2027 and any pre-readout data disclosures.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $1.80entry
- T+1 · 6d ago +5.00%α +3.68% · $1.89
- T+4 · todayOpen
- T+5 · in 3h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zentalis reported Q3 2026 net loss of $28.8M ($0.34 per share), narrower than the $0.52 consensus estimate, with cash of $228.9M providing runway into 1H 2028. The DENALI Part 2 topline readout was pushed to 1H 2027 (from year-end 2026), and management plans to discuss accelerated approval with the FDA in 2027, signaling a delay in the regulatory timeline.
Key Financial Metrics
Key Facts
- Q3 2026 net loss $28.8M ($0.34/share) vs consensus $-0.52, beat on EPS
- Cash $228.9M as of Sep 30, 2026, including $86.9M net from Aug 2026 follow-on offering of 26.45M shares
- DENALI Part 2 topline readout delayed from year-end 2026 to 1H 2027
- Management plans to discuss DENALI data with FDA in 2027 to assess accelerated approval opportunity
- DENALI Part 1b OS data: 15.9 months median OS in Cyclin E1-positive vs 7.5 months in negative patients
- Follow-on equity offering of 26.45M shares completed in August 2026, raising $86.9M net proceeds
Financial Impact
Net loss of $28.8M in Q3 2026, cash burn of ~$17M from Jun 30 to Sep 30 2026 (excluding offering proceeds), $86.9M raised in follow-on offering
Risk Factors
- DENALI Part 2 topline readout delayed to 1H 2027, pushing back potential regulatory submission
- Significant dilution from August 2026 follow-on offering (26.45M shares)
- No approved products; pre-revenue clinical-stage biotech with ongoing operating losses
- Accelerated approval pathway uncertain pending FDA feedback and evolving treatment landscape
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001725160-26-000069 |
| Document: zntlq32026corporatedeck.htm | 0001725160-26-000069 |
| Document: zntl-20261109.htm | 0001725160-26-000069 |
| Document: 0001725160-26-000069-index-headers.html | 0001725160-26-000069 |
| Document: 0001725160-26-000069-index.html | 0001725160-26-000069 |
| Document: 0001725160-26-000069.txt | 0001725160-26-000069 |
| 8-K Data (Synthetic) | 0001725160-26-000069 |
Track record
18 reports on ZNTL
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
- Nov 9, 20267d ago 8-K Bearish 5/10 Viewing Entry $1.80 Now $1.60 +11.11% settles Feb 8
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
- Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
- Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
- Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
- Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
- May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers